VSTM 241220 14.00C (VSTM241220C14000) Stock Options, News & Quotes

US OptionsDetailed Quotes

VSTM241220C14000

Watchlist

2.50
0.000.00%

15min DelayClose Nov 22 15:59 ET

0.00High0.00Low

Intraday

5D
Daily

News

Verastem Inc. Reports Increased Operating Expenses and Net Loss
TipRanksNov 21 22:54 ET
Byondis Appoints Louis Denis, M.D., as Chief Medical Officer
BusinesswireNov 19 01:11 ET
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
Moomoo NewsNov 7 07:31 ET · Ratings
A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14
Moomoo NewsNov 7 07:31 ET · Ratings
Verastem Price Target Lowered to $14 From $20 at Alliance Global Partners
TipRanksNov 7 07:06 ET
Express News | Corrected-Verastem Inc: Qtrly Adj Shr Loss $0.88 (Not '$0.71')
ReutersNov 6 17:09 ET

Comments

Tonyco

Oct 31 22:49

$Verastem (VSTM.US)$
Pretty damn good run so far. I only managed to hop on in Sept.

Jaguar8

Oct 31 15:01

NEWS

$Verastem (VSTM.US)$
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinibcombination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA ap...

Webcast today. Possible PR Monday.